Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse

PHASE2RecruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
OsteosarcomaEwing Sarcoma
Interventions
DRUG

Metformin Hydrochloride

"Metformin will be administrated according with patients body mass index (BMI).~Patients between 14 and 18 years old or with BMI ≤ 20: 500 mg two times a day Patients older than 18 years or with BMI \> 20: 850 mg two times a day.~In all cases, metformin will be administrated for 3 years maximum, unless there is a progression disease or if toxicity is verified."

Trial Locations (1)

Unknown

RECRUITING

Chemotherapy Div, Istituto Ortopedico Rizzoli, Bologna

All Listed Sponsors
lead

Istituto Ortopedico Rizzoli

OTHER